Sugi Predict

Sugi Predict / Compounds / SCHEMBL987913

SCHEMBL987913

SCHEMBL987913

COC(=O)[C@H](F)CN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ MAPT P10636 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ATM Q13315 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ NCOR2 Q9Y618 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10315708 1.00 KMT2A (0.44) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL84195 1.00 KMT2A (0.44) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL4151993 0.86 ACHE (0.47) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL3905042 0.86 L3MBTL1 (0.51) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL31489069 0.86 L3MBTL1 (0.51) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL16884048 0.86 L3MBTL1 (0.51) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL28865021 0.84 ALDH1A1 (0.46) KMT2AMEN1L3MBTL1MAPTALDH1A1
SCHEMBL10315700 0.84 ALDH1A1 (0.46) KMT2AMEN1L3MBTL1MAPTALDH1A1
SCHEMBL15688852 0.83 MEN1 (0.45) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL15688485 0.83 MEN1 (0.45) KMT2AMEN1NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735424-A1 PROCESSES FOR MAKING IRAK4 INHIBITORS GILEAD SCIENCES, INC. (US) 2026-05-06 — — EP disclosed
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 — — US disclosed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 — — EP disclosed
US-20250042906-A1 PROCESSES FOR MAKING IRAK4 INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 — — US disclosed
WO-2025006946-A1 PROCESSES FOR MAKING IRAK4 INHIBITORS GILEAD SCIENCES, INC. (US) 2025-01-02 — — WO disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 — — US disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 — — US disclosed
CN-115996932-A New macrocyclic LRRK2 kinase inhibitors 法国施维雅药厂 2023-04-21 — — CN disclosed
EP-4146658-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2023-03-15 — — EP disclosed
EP-3894416-B1 FERROPORTIN INHIBITORS AND METHODS OF USE GLOBAL BLOOD THERAPEUTICS INC (US) 2022-11-09 — — EP disclosed
US-20110015428-A1 Process for Producing Alpha-Fluoro-Beta-Amino Acids CENTRAL GLASS COMPANY, LIMITED (JP) 2011-01-20 — — US disclosed
US-20110015428-A1 Process for Producing Alpha-Fluoro-Beta-Amino Acids CENTRAL GLASS COMPANY, LIMITED (JP) 2011-01-20 — — US disclosed
US-20110015428-A1 Process for Producing Alpha-Fluoro-Beta-Amino Acids CENTRAL GLASS COMPANY, LIMITED (JP) 2011-01-20 — — US disclosed
EP-2246322-A1 PROCESS FOR PRODUCING -FLUORO- -AMINO ACIDS Central Glass Company, Limited (JP) 2010-11-03 — — EP disclosed
EP-2246322-A1 PROCESS FOR PRODUCING -FLUORO- -AMINO ACIDS Central Glass Company, Limited (JP) 2010-11-03 — — EP disclosed
US-20100130773-A1 PROCESS FOR THE SYNTHESIS OF ALKYL PHOSPHINIC ACIDS BY INITIATION OF AN AMINE AND AN AMINEOXIDE ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130773-A1 PROCESS FOR THE SYNTHESIS OF ALKYL PHOSPHINIC ACIDS BY INITIATION OF AN AMINE AND AN AMINEOXIDE ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
WO-2009133789-A1 PROCESS FOR PRODUCING α-FLUORO-β-AMINO ACIDS セントラル硝子株式会社 (JP) 2009-11-05 — — WO disclosed
WO-2008136746-A1 PROCESS FOR THE SYNTHESIS OF ALKYL PHOSPHINIC ACIDS BY INITIATION OF AN AMINE AND AN AMINEOXIDE ASTRAZENECA AB (SE) 2008-11-13 — — WO disclosed
WO-2008136745-A1 PROCESS FOR THE SYNTHESIS OF ALKYL PHOSPHINIC ACIDS BY INITIATION OF AN AMINE AND AN AMINEOXIDE ASTRAZENECA AB (SE) 2008-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors LRRK2, SNCA, ROS1 KMT2A 841/4885MEN1 3243/4885NPC1 1905/4885
US-20100130773-A1 PROCESS FOR THE SYNTHESIS OF ALKYL PHOSPHINIC ACIDS BY INITIATION OF AN AMINE AND AN AMINEOXIDE PPIP5K2, AGPS, PHPT1 KMT2A 768/4885MEN1 291/4885NPC1 4656/4885
US-20250042906-A1 PROCESSES FOR MAKING IRAK4 INHIBITORS IRAK4, IRAK3, IRAK2 KMT2A 1366/4885MEN1 3102/4885NPC1 2576/4885
US-20110015428-A1 Process for Producing Alpha-Fluoro-Beta-Amino Acids PHF2, BCAT2, EEF2 KMT2A 1310/4885MEN1 1200/4885NPC1 4270/4885
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, RIN1, GRK3 KMT2A 761/4885MEN1 1856/4885NPC1 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.